Prism Medico and Pharmacy Board of Directors
Get the latest insights into the leadership at Prism Medico and Pharmacy. Learn about the experienced professionals guiding the company's strategy and governance.
| Name | Position |
|---|---|
| Ms. Sakshi Laller | Whole Time Director |
| Mr. Davender Singh | Director |
| Mr. Pardeep Kumar | Independent Director |
| Mrs. Dinesh Kumar | Independent Director |
| Mr. Vishwambhar Dayal Gupta | Director |
Prism Medico and Pharmacy Share price
PRISMMEDI
17.85
0.68 (3.96%)Last updated on 4 Sep, 2025 | 13:44 IST
BUYSELL
Today's High
18.02
Today's Low
17.17
52 Week Low
11.62
52 Week High
37.20
The current prices are delayed, login to your account for live prices
LoginPrism Medico and Pharmacy FAQs
The board at Prism Medico and Pharmacy consists of experienced professionals, including Ms. Sakshi Laller , Mr. Davender Singh , and others, overseeing the company’s strategic and corporate governance.
Directors at Prism Medico and Pharmacy are typically nominated by the Nomination and Remuneration Committee and approved by shareholders, adhering to regulatory and governance standards. While this is the standard procedure, the exact process may differ depending on the company’s internal policies and governance framework.
As of the latest update, Ms. Sakshi Laller is the current chairman at Prism Medico and Pharmacy.
Executive directors at Prism Medico and Pharmacy are involved in day-to-day operations, while non-executive directors, including independents, provide oversight and strategic input. While this distinction is generally followed, the specific responsibilities of executive and non-executive directors may vary based on the company’s organisational structure and governance practices.
Yes, Prism Medico and Pharmacy adheres to all applicable SEBI and Companies Act provisions related to board structure, diversity, and independence.
At Prism Medico and Pharmacy, board members usually serve fixed terms as outlined in the company’s charter or governance policy, commonly ranging between three to five years, with the possibility of renewal based on performance, shareholder approval, and regulatory norms.